Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001126303) titled 'A study evaluating the safety and effectiveness of SIR9900 compared with placebo in adults with VEXAS syndrome' on Sept. 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Sironax USA, Inc.
Condition:
VEXAS syndrome
VEXAS syndrome
Inflammatory and Immune System - Autoimmune diseases
Human Genetics and Inherited Disorders - Other human genetics and inherited disorders
Blood - Other blood disorders
Intervention:
Participants will be randomised to receive SIR9900 20 mg, SIR9900 30 mg, or matching placebo orally once daily, together with...